Location History:
- Chatham, NJ (US) (2006)
- Edison, NJ (US) (2007 - 2010)
Company Filing History:
Years Active: 2006-2010
Title: Innovations of Wenqing Feng in Chemokine Receptor Inhibition
Introduction
Wenqing Feng is a notable inventor based in Edison, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit chemokine receptors. With a total of 4 patents to his name, his work has implications for various medical treatments.
Latest Patents
Feng's latest patents include innovative compounds such as piperidinyl piperidine derivatives and piperidinyl piperazine derivatives. These compounds are designed to act as inhibitors of the CCR5 receptors. The inventions provide methods for preparing these compounds, pharmaceutical compositions containing them, and methods for treating diseases associated with CCR5. Notably, these compounds have potential applications in treating Human Immunodeficiency Virus (HIV) and various autoimmune diseases, including arthritis and multiple sclerosis.
Career Highlights
Wenqing Feng is currently associated with Schering Corporation, where he continues to advance his research in pharmaceutical innovations. His work has been instrumental in developing new therapeutic strategies that address critical health challenges.
Collaborations
Feng has collaborated with esteemed colleagues such as Tze-Ming Chan and Anima Ghosal, contributing to a dynamic research environment that fosters innovation.
Conclusion
Wenqing Feng's contributions to the field of chemokine receptor inhibition highlight his role as a leading inventor in pharmaceutical chemistry. His innovative patents pave the way for new treatments that can significantly impact patient care.